{"id":3056,"date":"2026-08-23T10:28:44","date_gmt":"2026-08-23T10:28:44","guid":{"rendered":"https:\/\/valutednews.com\/?p=3056"},"modified":"2026-08-23T10:28:44","modified_gmt":"2026-08-23T10:28:44","slug":"moderna-keytruda-opdivo-ai-writing-readout-newsletter","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=3056","title":{"rendered":"Moderna, Keytruda, Opdivo, AI writing: Readout Newsletter"},"content":{"rendered":"
<\/div>

<\/p>\n

\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n

Cancer patients may be receiving higher doses and longer courses of expensive drugs than they need. Also, we see Moderna\u2019s stock swing some thanks to profit-taking, and\u2026\u00a0<\/p>\n

\u2026 I\u2019ve taken to channeling Diogenes these days, choosing lentils over tyranny. I recommend, they\u2019re most fibrous.\u00a0<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t